Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.23) by 35.9 percent. This is a 46.43 percent increase over losses of $(0.28) per share from the same period last year.